JP2023552195A5 - - Google Patents

Info

Publication number
JP2023552195A5
JP2023552195A5 JP2023533878A JP2023533878A JP2023552195A5 JP 2023552195 A5 JP2023552195 A5 JP 2023552195A5 JP 2023533878 A JP2023533878 A JP 2023533878A JP 2023533878 A JP2023533878 A JP 2023533878A JP 2023552195 A5 JP2023552195 A5 JP 2023552195A5
Authority
JP
Japan
Prior art keywords
peg
lnp
lipid
immune cell
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023533878A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552195A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/072745 external-priority patent/WO2022120388A2/en
Publication of JP2023552195A publication Critical patent/JP2023552195A/ja
Publication of JP2023552195A5 publication Critical patent/JP2023552195A5/ja
Pending legal-status Critical Current

Links

JP2023533878A 2020-12-04 2021-12-03 イオン化可能なカチオン性脂質および脂質ナノ粒子ならびにその合成および使用の方法 Pending JP2023552195A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063121801P 2020-12-04 2020-12-04
US63/121,801 2020-12-04
US202163166205P 2021-03-25 2021-03-25
US63/166,205 2021-03-25
US202163169395P 2021-04-01 2021-04-01
US202163169296P 2021-04-01 2021-04-01
US63/169,395 2021-04-01
US63/169,296 2021-04-01
US202163172024P 2021-04-07 2021-04-07
US63/172,024 2021-04-07
PCT/US2021/072745 WO2022120388A2 (en) 2020-12-04 2021-12-03 Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026078720A Division JP2026129957A (ja) 2020-12-04 2026-05-08 イオン化可能なカチオン性脂質および脂質ナノ粒子ならびにその合成および使用の方法

Publications (2)

Publication Number Publication Date
JP2023552195A JP2023552195A (ja) 2023-12-14
JP2023552195A5 true JP2023552195A5 (cg-RX-API-DMAC10.html) 2024-12-10

Family

ID=79287892

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533878A Pending JP2023552195A (ja) 2020-12-04 2021-12-03 イオン化可能なカチオン性脂質および脂質ナノ粒子ならびにその合成および使用の方法

Country Status (12)

Country Link
US (1) US20220218614A1 (cg-RX-API-DMAC10.html)
EP (1) EP4256067A2 (cg-RX-API-DMAC10.html)
JP (1) JP2023552195A (cg-RX-API-DMAC10.html)
KR (1) KR20230123480A (cg-RX-API-DMAC10.html)
AU (1) AU2021393593A1 (cg-RX-API-DMAC10.html)
CA (1) CA3201219A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023007408A2 (cg-RX-API-DMAC10.html)
IL (1) IL303373A (cg-RX-API-DMAC10.html)
MX (1) MX2023006604A (cg-RX-API-DMAC10.html)
PH (1) PH12023500013A1 (cg-RX-API-DMAC10.html)
TW (1) TW202241458A (cg-RX-API-DMAC10.html)
WO (1) WO2022120388A2 (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12011507B2 (en) 2022-04-01 2024-06-18 Nanovation Therapeutics Inc. MRNA delivery composition
CN119630705A (zh) * 2022-06-14 2025-03-14 阿布林克斯有限公司 靶向t细胞受体的免疫球蛋白单可变结构域
WO2024079046A1 (en) * 2022-10-10 2024-04-18 Zelarion Malta Limited Anti-cd2 antibodies for type 1 diabetes
EP4630061A1 (en) * 2022-12-08 2025-10-15 Nanovation Therapeutics Inc. Lipid nanoparticles comprising elevated neutral lipid and a targeting moiety for targeted delivery of nucleic acid
JP2026512425A (ja) * 2023-03-30 2026-04-16 オーエスイー・イミュノセラピューティクス 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
WO2024200820A1 (en) * 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
EP4694867A2 (en) * 2023-04-13 2026-02-18 Massachusetts Institute of Technology Lipid nanoparticles for delivery of agents
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
EP4758176A1 (en) * 2023-07-31 2026-06-17 Jibe Therapeutics, Inc. Compositions for redirecting immunoglobulins to immune cells
AU2024342487A1 (en) * 2023-09-13 2026-04-30 Tessera Therapeutics, Inc. Lipid nanoparticles for delivery of therapeutic payloads to cells
KR20260094765A (ko) * 2023-10-13 2026-06-23 나노셀 테라퓨틱스 홀딩스 비.브이. 면역 이펙터 세포로의 제제 전달을 위한 수단 및 방법
IL330028A (en) * 2023-12-13 2026-08-01 Tidal Therapeutics Inc Ionizable cationic lipids and lipid nanoparticles, and methods for their synthesis and use
IL328626A (en) * 2023-12-15 2026-07-01 Capstan Therapeutics Inc Humanized anti-CD8 antibodies and their uses
AU2024413489A1 (en) * 2023-12-29 2026-07-16 Samyang Biopharm Corporation Nanoparticle composition for drug delivery
WO2025169168A1 (en) * 2024-02-09 2025-08-14 Nanocell Therapeutics Holdings B.V. Extracorporeal transfection of immune effector cells
WO2025184694A1 (en) * 2024-03-04 2025-09-12 The University Of Melbourne Nanoparticles and uses thereof
US20250381150A1 (en) 2024-03-08 2025-12-18 Genzyme Corporation Lipid nanoparticles
WO2025213153A2 (en) * 2024-04-05 2025-10-09 Transcera Inc. Compounds for lysosomal degradation of target proteins
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026029040A1 (ja) * 2024-07-29 2026-02-05 日油株式会社 アミノ脂質及び脂質ナノ粒子
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof
WO2026080826A1 (en) * 2024-10-10 2026-04-16 Generation Bio Co. Bispecific stealth lipid nanoparticle compositions for cell targeting
WO2026083328A1 (en) 2024-10-18 2026-04-23 Precision Biosciences, Inc. Base editing nucleotide sequences using homology directed repair
WO2026083329A1 (en) 2024-10-18 2026-04-23 Precision Biosciences, Inc. Methods of nuclease-initiated homology directed repair and replacement and compositions and uses thereof
WO2026090137A1 (en) * 2024-10-22 2026-04-30 Genzyme Corporation Process for inserting targeting ligand into a lipid nanoparticle encapsulating nucleic acid and compositions produced therefrom
WO2026099382A1 (en) * 2024-11-06 2026-05-15 Nanocell Therapeutics Holdings B.V. Means and methods for delivery of agents to immune effector cells
WO2026142951A1 (en) 2024-12-23 2026-07-02 Genzyme Corporation Pharmaceutical system
WO2026141629A1 (ja) * 2024-12-27 2026-07-02 日東電工株式会社 脂質ナノ粒子

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
EP0568332B1 (en) 1992-04-28 1999-07-28 Sumitomo Rubber Industries, Ltd. Solid golf ball
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
JP3626187B2 (ja) 1993-06-07 2005-03-02 バイカル インコーポレイテッド 遺伝子治療に適するプラスミド
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US6849258B1 (en) 1997-07-18 2005-02-01 Universite Catholique De Louvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
NZ545314A (en) 2003-08-04 2009-03-31 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble CTLA4 molecule
JP2007521234A (ja) 2003-08-12 2007-08-02 ウィリアム エム ヤーブロー 尋常性ざ瘡の治療薬及び使用方法
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン.ヴェー. Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
WO2009100140A1 (en) 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
AU2009290543B2 (en) 2008-09-12 2015-09-03 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
MX2011010681A (es) 2009-04-10 2012-01-20 Ablynx Nv Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
ES2613498T3 (es) * 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
US8569256B2 (en) * 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US20130017223A1 (en) 2009-12-18 2013-01-17 The University Of British Columbia Methods and compositions for delivery of nucleic acids
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
WO2015011633A1 (en) * 2013-07-23 2015-01-29 Protiva Biotherapeutics, Inc. Compositions and methods for delivering messenger rna
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
HUE050159T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
LT3248986T (lt) 2014-05-16 2022-03-25 Ablynx Nv Imunoglobulino kintami domenai
EP3247398A4 (en) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016176330A1 (en) * 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
EP3303598B1 (en) * 2015-05-26 2025-03-19 Ramot at Tel-Aviv University Ltd. Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
US20180271998A1 (en) * 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
CN111542338B (zh) * 2017-12-27 2024-06-18 武田药品工业株式会社 含核酸脂质纳米粒子及其用途
US20200149070A1 (en) * 2018-04-24 2020-05-14 Ligandal, Inc. Methods and compositions for genome editing
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAx抗-CD3抗體及其用途
JP2021530545A (ja) 2018-07-23 2021-11-11 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. 同種異系の細胞療法における抗−cd2抗体薬物コンジュゲート(adc)の使用

Similar Documents

Publication Publication Date Title
JP7542257B2 (ja) 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法
US20160361317A1 (en) Compositions comprising rank/rankl antagonists and related compounds for treating pain
JP2025505603A (ja) 細胞への標的化送達のための薬剤および方法
US20250281405A1 (en) Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
KR20250007062A (ko) Epo 수용체 효능제 및 길항제
CN117642429A (zh) 用于治疗cldn6阳性癌症的编码cldn6和cds结合元件的试剂
WO2022067091A1 (en) Systems and methods for expressing biomolecules in a subject
US20250235532A1 (en) Polymer-lipid hybrid nanoparticles comprising a lipid and a block copolymer as well as methods of making and uses thereof
WO2020053325A1 (en) Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
WO2025087303A1 (en) Lipid nanoparticle with non-covalent bifunctional binders for active targeting
JP2012506371A (ja) 樹状細胞を標的とするための組成物
JP2024522607A (ja) 治療薬の標的化送達のための組成物及び方法
RU2024139944A (ru) Ионизируемые катионные липиды и липидные наночастицы, а также способы их синтеза и применения
JP2024522316A5 (cg-RX-API-DMAC10.html)
US20250381150A1 (en) Lipid nanoparticles
CN120359047A (zh) 用于靶向递送治疗剂的组合物和方法
EP4652282A2 (en) Compositions for targeting muscle cells and uses thereof
WO2024092352A1 (en) Compositions that recruit and activate antigen presenting cells
HK40113807A (en) Agents and methods for targeted delivery of nucleic acids to cells
HK40114081A (en) Agents and methods for targeted delivery to cells
CN118973618A (zh) 用于将核酸靶向递送至细胞的药剂和方法
CN118973619A (zh) 用于靶向递送至细胞的药剂和方法
WO2026085300A1 (en) Compositions and methods
WO2026034573A1 (ja) Cd320に結合する抗体およびその断片、並びに前記抗体を含む抗体薬物コンジュゲート
WO2022097634A1 (ja) 血管新生依存性疾患治療に使用される医薬用組成物